Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... CO (PRWEB) August 27, 2014 Flagship ... analysis services to the pharmaceutical and medical device ... expansion. The fast growing company has consolidated its ... Aurora and Boulder to Westminster, CO, just north of ... Histology Lab, 7575 W. 103rd Ave., Suite 100, Westminster, ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014" ... Stable Isotope Ratio Mass Spectrometer Industry Report 2014 is ... of the global isotope ratio mass spectrometer industry. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:8/27/2014)... , Aug. 27, 2014 Tris Pharma, a ... technologies, today announced that it has been selected as ... Industry Association,s 2014 Awards for Excellence competition ... an independent panel of judges from SCORE (Counselors to ... winners will be honored at a gala event to ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... 7 ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading ... cells, announced today that it will be,participating in the ... 10, 2008., The Company,s presentation by Dr. William ... Standard Time (11:50 am, Pacific Standard,Time), and will be ...
... cubes and spheres move aside. Tiny gold stars, smaller ... for new approaches to medical diagnoses or testing for environmental ... wide spectrum of sciences, a new study by Duke University ... stars may shine above all the rest for certain applications. ...
... Upon a Proven Class of Drugs With Greater Tumor ... (Nasdaq: ONXX ) today announced that it has,in-licensed ... Limited based in the United Kingdom. Under the terms ... BGC 945 and all of its,related patents. Onyx will ...
Cached Biology Technology:ThermoGenesis Presentation at Rodman & Renshaw Conference 2Gold nanostar shape of the future 2Gold nanostar shape of the future 3Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 2Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International 3
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... of Warwick have provided the first evidence that ... linked to early signs of dementia. , Published ... that the absence of the protein MK2/3 promotes ... nervous system. These changes were shown to have ... including restricted learning and memory formation capabilities. , ...
(Date:8/26/2014)... In recent years, increasing pressure from policymakers, consumers, ... targets that go beyond reducing the pollutants they ... and lakes. Today companies must also assess environmental ... the mining of primary materials to the use ... has given rise to the discipline known as ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2Yale journal explores advances in sustainable manufacturing 2
... 2011 -- Research presented today at the 31st Annual meeting ... Meeting has found that three proteins known as XIAP, BID, ... progesterone treatments in the prevention of preterm labor. They ... The proteins prevent preterm birth by hindering ...
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... the 4th Congress of the International Society for Hemodialysis ... "The Treatment of HCV with Affinity Plasmapheresis." The conference ...
... today at the 31st Annual meeting of the Society for ... three proteins known as XIAP, BID, and Bcl-2 are responsible ... prevention of preterm labor. They may also play an ... proteins prevent preterm birth by hindering apoptosis the normal, ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 2Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 3Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 4Aethlon Medical to Present at 4th Congress of the International Society for Hemodialysis in India 5New research helps explain how progesterone preventspreterm birth 2
... The new D-LUX Detection Platform combines ... provide the most sensitive, specific, and ... Invitrogens D-LUX Detection Platform offers exceptional ... to TaqMan probes, high signal/background ratio, ...
...
Request Info...
... Blood is aseptically collected via cardiac puncture ... Zealand White, mixed sex). It is then centrifuged ... pooled, sterile filtered and bottled at 4C then ... IF YOU HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU ...
Biology Products: